The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | Pembrolizumab plus chemotherapy for esophageal cancer: KEYNOTE-590
Elizabeth C. Smyth, MD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the results of the KEYNOTE-590 (NCT03189719) Phase III trial. Pembrolizumab plus chemotherapy was compared to chemotherapy alone in treatment-naive esophageal cancer. Both endpoints, progression-free survival and overall survival, were met. However, further research is needed for adenocarcinomas as response to treatment is not as long as squamous cell carcinomas. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
